Treatment of Relapsed/Refractory Ph- ALL
Released On
July 29, 2022
Expires On
July 29, 2023
Media Type
Internet
Completion Time
30 minutes
Specialty
Hematology-Oncology
Topic(s)
Leukemia, Lymphoma, Oncology
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy.
This activity is supported by an educational grant from Pfizer.
Credit Available
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
- Nurses — 0.5 contact hours
All other health care professionals completing this course will be issued a statement of participation.
Target Audience
The target audience for this initiative includes hematology/oncology physicians, nurses, and other members of the multidisciplinary cancer care team involved in the management of patients with acute lymphocytic leukemia.
Program Overview
This activity is the third in a series of four educational activities focusing on the treatment of relapsed/refractory ALL. Dr. Ayman Qasrawi from the University of Kentucky Markey Cancer Center discusses diagnosis and treatment options and will walk through a case study of a patient with Ph- ALL.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who could benefit from CD22-directed ADC therapy using current practice guideline recommendations
Faculty
Ayman Qasrawi, MD
Assistant Professor
Division of Hematology & BMT
University of Kentucky
Lexington, KY
Nurse Planner:
Kirsten Roblee, MHI, BSN, RN, OCN
Administrative Nurse Manager, Oncology Infusion Services
Dublin Methodist Hospital & Grady Memorial Hospital
Ohio Health
Columbus, OH
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
Physicians
The France Foundation designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The France Foundation designates this activity for 0.5 contact hours.
Disclosures of Conflicts of Interest
Planning Committee
Ayman Qasrawi, MD has no financial relationships to disclose.
Staff/Content Reviewers
Erika Fox has no financial relationships to disclose.
Heather Tarbox, MPH has no financial relationships to disclose.
Heidi Thompson, PhD has no financial relationships to disclose.
Kirsten Kozub has no financial relationships to disclose.
Kirsten Roblee, MHI, BSN, RN, OCN has no financial relationships to disclose.
Instructions for Participation and Credit
Technical Requirements: http://www.francefoundation.com/general-requirements.html
- There are no fees for participating in and receiving credit for this activity
- Review the activity objectives and CME/CE information
- Complete the CME/CE activity
- Complete the online posttest. A score of at least 80% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ASTCT, and the commercial supporter(s) assume no liability for the information herein.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.